Dov A. Goldstein's most recent trade in Gain Therapeutics Inc was a trade of 25,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on July 15, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gain Therapeutics Inc | Dov A. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2026 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| BioAge Labs Inc | Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.38 per share. | 23 Apr 2026 | 3,542 | 36,575 | - | 4.4 | 15,514 | Common Stock |
| BioAge Labs Inc | Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Apr 2026 | 3,542 | 155,833 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.38 per share. | 01 Feb 2026 | 3,541 | 29,491 | - | 4.4 | 15,510 | Common Stock |
| BioAge Labs Inc | Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2026 | 3,541 | 162,917 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.38 per share. | 16 Jan 2026 | 3,542 | 25,950 | - | 4.4 | 15,514 | Common Stock |
| BioAge Labs Inc | Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2026 | 3,542 | 166,458 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2026 | 27,000 | 92,587 | - | - | Stock Option (Right to Buy) | |
| BioAge Labs Inc | Dov A. Goldstein | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.39 per share. | 13 Jan 2026 | 27,000 | 49,408 | - | 8.4 | 226,530 | Common Stock |
| BioAge Labs Inc | Dov A. Goldstein | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.54 per share. | 13 Jan 2026 | 11,663 | 24,331 | - | 20.5 | 239,549 | Common Stock |
| BioAge Labs Inc | Dov A. Goldstein | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.43 per share. | 13 Jan 2026 | 8,974 | 40,434 | - | 18.4 | 165,371 | Common Stock |
| BioAge Labs Inc | Dov A. Goldstein | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.45 per share. | 13 Jan 2026 | 4,440 | 35,994 | - | 19.5 | 86,370 | Common Stock |
| BioAge Labs Inc | Dov A. Goldstein | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.08 per share. | 13 Jan 2026 | 1,923 | 22,408 | - | 21.1 | 40,538 | Common Stock |
| Coya Therapeutics Inc | Dov A. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Coya Therapeutics Inc | Dov A. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 17,557 | 0 | - | - | Stock Option (right to buy) | |
| Coya Therapeutics Inc | Dov A. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.09 per share. | 18 Aug 2025 | 17,557 | 27,557 | - | 1.1 | 19,137 | Common Stock, par value $0.0001 per share |
| Gain Therapeutics Inc | Dov A. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2025 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Coya Therapeutics Inc | Dov A. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| BioAge Labs Inc | Dov A. Goldstein | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 170,000 | 170,000 | - | - | Stock Option (Right to Buy) | |
| Coya Therapeutics Inc | Dov A. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Gain Therapeutics Inc | Dov A. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Coya Therapeutics Inc | A. Dov Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Gain Therapeutics Inc | Dov A. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 10,500 | 10,500 | - | - | Stock Option (right to buy) | |
| Coya Therapeutics Inc | Dov A. Goldstein | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 03 Jan 2023 | 10,000 | 10,000 | - | - | Common Stock, par value $0.0001 per share | |
| Coya Therapeutics Inc | Dov A. Goldstein | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 03 Jan 2023 | 5,000 | 5,000 | - | - | Warrant to Purchase Common Stock | |
| Gain Therapeutics Inc | Dov A. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Sep 2022 | 10,500 | 10,500 | - | - | Stock Option (right to buy) | |
| NeuBase Therapeutics Inc | Dov A. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2022 | 37,600 | 37,600 | - | - | Stock option (right to buy) | |
| NeuBase Therapeutics Inc | Dov A. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2021 | 38,135 | 38,135 | - | - | Stock option (right to buy) |